DLA Piper advises Haymaker Acquisition Corp. III in the closing of its business combination with BioTe Holdings, LLC

DLA Piper advised Haymaker Acquisition Corp. III, a special purpose acquisition company, in the closing of its business combination with BioTe Holdings, LLC, a high-growth, differentiated medical practice-building business within the hormone optimization space. Upon the closing of the transaction, which was approved by Haymaker’s stockholders, Haymaker was renamed biote Corp, and its Class A common stock and warrants will trade under the symbols “BTMD” and “BTMDW,” respectively, on the Nasdaq Stock Exchange.

biote delivers a comprehensive, end-to-end platform that provides practitioners the needed components to develop and implement a successful hormone optimization program for their patient populations. These components include training and certification, practice and inventory management softwares, information surrounding hormone replacement therapy products, and digital and point-of-care marketing support, among others.

Since its founding in 2012, biote has grown its network of medical providers to 4,700 practitioners in the US, and the combined business will allow biote to accelerate its growth in new geographies and its core markets.

“Congrats to Haymaker in its business combination with biote. On behalf of our deal team, it was an honor working with Haymaker and combining our deep SPAC, M&A, capital markets and tax capabilities with our experience in the consumer and healthcare sectors to support this transaction and biote’s future growth,” said Sidney Burke, the DLA Piper partner who led the team.

In addition to Burke (New York), the DLA Piper team advising Haymaker included partners Stephen Alicanti and Drew Young in New York and numerous other colleagues across the country.

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 12 consecutive years, according to Mergermarket.

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.